Notice of Listing of Members of the National Institutes of Health's Senior Executive Service 2021 Performance Review Board (PRB), 43669-43670 [2021-17039]

Download as PDF Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices 9. TEKTURNA (aliskiren hemifumarate) 10. VIMOVO (naproxen/esomeprazole magnesium) 11. VIREAD (tenofovir disoproxil fumarate) 12. XOFLUZA (baloxavir marboxil) Center for Devices and Radiological Health 1. CONTEGRA PULMONARY VALVED CONDUIT (Humanitarian Device Exemption (HDE)) 2. ELANA SURGICAL KIT (HDE) 3. ENTERRA THERAPY SYSTEM (HDE) 4. LIPOSORBER LA–15 SYSTEM (HDE) 5. MEDTRONIC ACTIVA DYSTONIA THERAPY (HDE) 6. MINIMALLY INVASIVE DEFORMITY CORRECTION (MID–C) SYSTEM 7. PLEXIMMUNE IN–VITRO DIAGNOSTIC TEST (HDE) 8. PULSERIDER ANEURYSM NECK RECONSTRUCTION DEVICE (HDE) 9. THE TETHER—VERTEBRAL BODY TETHERING SYSTEM Dated: August 5, 2021. Lauren K. Roth, Acting Principal Associate Commissioner for Policy. [FR Doc. 2021–17041 Filed 8–9–21; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jbell on DSKJLSW7X2PROD with NOTICES Office of the Director, National Institutes of Health; Notice of Meeting Notice is hereby given of a meeting of the HEAL (Helping to End Addiction Long-Term) Multi-Disciplinary Working Group. The meeting will be open to the public as indicated below via NIH Videocast. Individuals who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The program documents and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the program documents, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: HEAL MultiDisciplinary Working Group (MDWG) Meeting. VerDate Sep<11>2014 17:05 Aug 09, 2021 Jkt 253001 Date: September 1–2, 2021. Open: September 01, 2021, 10:30 a.m. to 11:30 a.m. Closed: September 02, 2021, 11:30 a.m. to 4:30 p.m. Closed: September 02, 2021, 10:30 a.m. to 3:45 p.m. Agenda: Provide an update on Helping to End Addiction Long-Term (HEAL) Initiative projects and obtain expertise from MDWG relevant to the NIH HEAL Initiative and to specific HEAL projects. Videocast: The open portion of the meeting will be live webcast at: https:// videocast.nih.gov/. Place: National Institutes of Health, Building 1, Wilson Hall, 1 Center Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Rebecca G Baker, Ph.D., Office of the Director, National Institutes of Health, 1 Center Drive, Room 103A, Bethesda, MD 20892, (301) 402–1994, Rebecca.baker@nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Office of the Director for the NIH HEAL Initiative website: https://heal.nih.gov/news where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: August 5, 2021. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–17012 Filed 8–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Center for Scientific Review Advisory Council. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. URL for virtual access:—https:// videocast.nih.gov/watch=42556 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 Name of Committee: Center for Scientific Review Advisory Council. Date: September 27, 2021. Time: 1:00 p.m. to 4:30 p.m. Agenda: Provide advice to the Director, Center for Scientific Review (CSR), on matters related to planning, execution, conduct, support, review, evaluation, and receipt and referral of grant applications at CSR. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Bruce Reed, Ph.D., Deputy Director, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–9159, reedbr@mail.nih.gov. Information is also available on the Institute’s/Center’s home page: https:// public.csr.nih.gov/AboutCSR/Organization/ CSRAdvisoryCouncil, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: August 5, 2021. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–17043 Filed 8–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Listing of Members of the National Institutes of Health’s Senior Executive Service 2021 Performance Review Board (PRB) AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Institutes of Health (NIH) announces the persons who will serve on the National Institutes of Health’s Senior Executive Service 2021 Performance Review Board. FOR FURTHER INFORMATION CONTACT: For further information about the NIH Performance Review Board, contact Mr. Kha Nguyen, Director, Division of Senior and Scientific Executive Management, Office of Human Resources, National Institutes of Health, Building 31, Room 1C31P, Bethesda, Maryland 20892, telephone 301.594.3022 (not a toll-free number), email kha.nguyen@nih.gov. SUPPLEMENTARY INFORMATION: This action is being taken in accordance with SUMMARY: Center for Scientific Review; Notice of Meeting 43669 E:\FR\FM\10AUN1.SGM 10AUN1 43670 Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices Title 5, U.S.C., section 4314 (c) (4), which requires that members of performance review boards be appointed in a manner to ensure consistency, stability, and objectivity in performance appraisals and requires that notice of the appointment of an individual to serve as a member be published in the Federal Register. The following persons will serve on the NIH Performance Review Board, which oversees the evaluation of performance appraisals of NIH Senior Executive Service (SES) members: Alfred Johnson, Chair Courtney Billet Michael Gottesman Darla Hayes Michael Lauer Kathleen Stephan Lawrence Tabak DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: Multi-Domain Amphipathic Helical Peptide for Use as A Human Therapeutic in Patients With Atherosclerotic Cardiovascular Disease, Including Patients Undergoing Cardiovascular Surgery Who Are at risk of Acute Kidney Injury AGENCY: [FR Doc. 2021–17039 Filed 8–9–21; 8:45 am] BILLING CODE 4140–01–P jbell on DSKJLSW7X2PROD with NOTICES E–114–2004–0– US–01. E–114–2004–0– PCT–02. E–114–2004–0– AU–03. E–114–2004–0– CA–04. E–114–2004–0– EP–05. E–114–2004–0– JP–06. E–114–2004–0– US–07. E–114–2004–0– US–08. E–114–2004–0– US–09. E–114–2004–0– CH–11. E–114–2004–0– DE–12. E–114–2004–0– ES–13. E–114–2004–0– FR–14. E–114–2004–0– GB–15. E–114–2004–0– IT–16. E–114–2004–0– US–17. VerDate Sep<11>2014 Patent Application No. Title Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. Multi-Domain Amphipathic ods Of Their Use. All U.S. and foreign patents and applications claiming priority to any member of the above. The patent rights in these inventions have been assigned or exclusively 17:05 Aug 09, 2021 Jkt 253001 section of this notice. This is a first notice intended to apprise the public of a change in prospective licensee of the subject intellectual property rights in the stated field of use. Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute on or before August 25, 2021 will be considered. DATES: Requests for copies of the patent application, inquiries, and ACTION: Notice. comments relating to the contemplated an exclusive patent license should be SUMMARY: The National Heart, Lung, and directed to: Michael Davis, J.D., Ph.D., Blood Institute, an institute of the Senior Technology Transfer Manager, 31 National Institutes of Health, Center Drive Room 4A29, MSC2479, Department of Health and Human Bethesda, MD 20892–2479, phone Services, is contemplating the grant of number 301–451–9032, or an exclusive patent license to Phyxius michael.davis4@nih.gov. Therapeutics, Inc., a start-up company incorporated as a C corporation under SUPPLEMENTARY INFORMATION: the laws of the state of Delaware, to Intellectual Property practice the inventions covered by the HHS. Dated: August 2, 2021. Lawrence A. Tabak, Principal Deputy Director, National Institutes of Health. NIH REF No. National Institutes of Health, patent estate listed in the SUPPLEMENTARY INFORMATION ADDRESSES: Filing Date Issued Patent No. Issue Date Helical Peptides And Meth- 60/619,392 10/15/04 ........................ ........................ Helical Peptides And Meth- PCT/US2005/ 10/14/05 ........................ ........................ Helical Peptides And Meth- 2005295640 10/14/05 2005295640 11/10/11 Helical Peptides And Meth- 2584048 10/14/05 2584048 08/09/16 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 2007–536912 10/14/05 5,091,679 09/21/12 Helical Peptides And Meth- 11/577,259 04/13/07 7,572,771 08/11/09 Helical Peptides And Meth- 12/497,443 07/02/09 8,071,746 12/06/11 Helical Peptides And Meth- 12/766,761 04/23/10 8,148,323 04/03/12 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 05815961.7 10/14/05 1812474 05/26/10 Helical Peptides And Meth- 13/407,132 02/28/12 8,835,378 09/16/14 licensed to the Government of the United States of America. The prospective exclusive license territory may be worldwide and in fields of use that may be limited to use as a human therapeutic in patients with PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 atherosclerotic cardiovascular disease (ASCVD), including patients undergoing cardiovascular surgery who are at risk of acute kidney injury. The patents listed above cover an invention directed to peptides or E:\FR\FM\10AUN1.SGM 10AUN1

Agencies

[Federal Register Volume 86, Number 151 (Tuesday, August 10, 2021)]
[Notices]
[Pages 43669-43670]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17039]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Listing of Members of the National Institutes of 
Health's Senior Executive Service 2021 Performance Review Board (PRB)

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health (NIH) announces the persons 
who will serve on the National Institutes of Health's Senior Executive 
Service 2021 Performance Review Board.

FOR FURTHER INFORMATION CONTACT: For further information about the NIH 
Performance Review Board, contact Mr. Kha Nguyen, Director, Division of 
Senior and Scientific Executive Management, Office of Human Resources, 
National Institutes of Health, Building 31, Room 1C31P, Bethesda, 
Maryland 20892, telephone 301.594.3022 (not a toll-free number), email 
[email protected].

SUPPLEMENTARY INFORMATION: This action is being taken in accordance 
with

[[Page 43670]]

Title 5, U.S.C., section 4314 (c) (4), which requires that members of 
performance review boards be appointed in a manner to ensure 
consistency, stability, and objectivity in performance appraisals and 
requires that notice of the appointment of an individual to serve as a 
member be published in the Federal Register.
    The following persons will serve on the NIH Performance Review 
Board, which oversees the evaluation of performance appraisals of NIH 
Senior Executive Service (SES) members:

Alfred Johnson, Chair
Courtney Billet
Michael Gottesman
Darla Hayes
Michael Lauer
Kathleen Stephan
Lawrence Tabak

    Dated: August 2, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2021-17039 Filed 8-9-21; 8:45 am]
BILLING CODE 4140-01-P